Aurisco Pharmaceutical Co Ltd Asset Resilience Ratio

Latest as of June 2025: 4.08%

Aurisco Pharmaceutical Co Ltd asset resilience ratio. Aurisco Pharmaceutical Co Ltd (605116) has an Asset Resilience Ratio of 4.08% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 605116 defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Liquid Assets

CN¥159.28 Million

≈ $23.31 Million USD Cash + Short-term Investments

Total Assets

CN¥3.90 Billion

≈ $571.06 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio of Aurisco Pharmaceutical Co Ltd (2024–2024)

Asset resilience ratio of Aurisco Pharmaceutical Co Ltd from 2024 to 2024. This chart shows how Aurisco Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Read 605116 current and long-term liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Aurisco Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Aurisco Pharmaceutical Co Ltd assets under control.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥159.28 Million	4.08%
Total Liquid Assets	CN¥159.28 Million	4.08%

Asset Resilience Insights

Limited Liquidity: Aurisco Pharmaceutical Co Ltd maintains only 4.08% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Aurisco Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Aurisco Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	15.95%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Tubize-Fin BR:TUB	Biotechnology	2.50%
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	Biotechnology	62.31%
3SBio Inc F:83B	Biotechnology	10.64%
Galapagos N.V. AS:GLPG	Biotechnology	86.45%
Chengzhi Shareholding Co Ltd SHE:000990	Biotechnology	6.12%

Aurisco Pharmaceutical Co Ltd Asset Resilience Ratio by Year (2024–2024)

Aurisco Pharmaceutical Co Ltd asset resilience ratio by year from 2024 to 2024. The table below shows the annual Asset Resilience Ratio data for Aurisco Pharmaceutical Co Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	7.73%	CN¥299.83 Million ≈ $43.87 Million	CN¥3.88 Billion ≈ $567.39 Million	--

pp = percentage points

About Aurisco Pharmaceutical Co Ltd

SHG:605116 China Biotechnology

Market Cap

$1.11 Billion

CN¥7.56 Billion CNY

Market Cap Rank

#8168 Global

#1843 in China

Share Price

CN¥18.60

Change (1 day)

-0.96%

52-Week Range

CN¥17.46 - CN¥34.43

All Time High

CN¥34.43